Cargando…

Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA

We assessed video directly observed therapy (VDOT) for monitoring tuberculosis treatment in 5 health districts in California, USA, to compare adherence between 174 patients using VDOT and 159 patients using in-person directly observed therapy (DOT). Multivariable linear regression analyses identifie...

Descripción completa

Detalles Bibliográficos
Autores principales: Garfein, Richard S., Liu, Lin, Cuevas-Mota, Jazmine, Collins, Kelly, Muñoz, Fatima, Catanzaro, Donald G., Moser, Kathleen, Higashi, Julie, Al-Samarrai, Teeb, Kriner, Paula, Vaishampayan, Julie, Cepeda, Javier, Bulterys, Michelle A., Martin, Natasha K., Rios, Phillip, Raab, Fredric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154139/
https://www.ncbi.nlm.nih.gov/pubmed/30226154
http://dx.doi.org/10.3201/eid2410.180459
_version_ 1783357644507971584
author Garfein, Richard S.
Liu, Lin
Cuevas-Mota, Jazmine
Collins, Kelly
Muñoz, Fatima
Catanzaro, Donald G.
Moser, Kathleen
Higashi, Julie
Al-Samarrai, Teeb
Kriner, Paula
Vaishampayan, Julie
Cepeda, Javier
Bulterys, Michelle A.
Martin, Natasha K.
Rios, Phillip
Raab, Fredric
author_facet Garfein, Richard S.
Liu, Lin
Cuevas-Mota, Jazmine
Collins, Kelly
Muñoz, Fatima
Catanzaro, Donald G.
Moser, Kathleen
Higashi, Julie
Al-Samarrai, Teeb
Kriner, Paula
Vaishampayan, Julie
Cepeda, Javier
Bulterys, Michelle A.
Martin, Natasha K.
Rios, Phillip
Raab, Fredric
author_sort Garfein, Richard S.
collection PubMed
description We assessed video directly observed therapy (VDOT) for monitoring tuberculosis treatment in 5 health districts in California, USA, to compare adherence between 174 patients using VDOT and 159 patients using in-person directly observed therapy (DOT). Multivariable linear regression analyses identified participant-reported sociodemographics, risk behaviors, and treatment experience associated with adherence. Median participant age was 44 (range 18–87) years; 61% of participants were male. Median fraction of expected doses observed (FEDO) among VDOT participants was higher (93.0% [interquartile range (IQR) 83.4%–97.1%]) than among patients receiving DOT (66.4% [IQR 55.1%–89.3%]). Most participants (96%) would recommend VDOT to others; 90% preferred VDOT over DOT. Lower FEDO was independently associated with US or Mexico birth, shorter VDOT duration, finding VDOT difficult, frequently taking medications while away from home, and having video-recording problems (p<0.05). VDOT cost 32% (range 6%–46%) less than DOT. VDOT was feasible, acceptable, and achieved high adherence at lower cost than DOT.
format Online
Article
Text
id pubmed-6154139
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-61541392018-10-01 Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA Garfein, Richard S. Liu, Lin Cuevas-Mota, Jazmine Collins, Kelly Muñoz, Fatima Catanzaro, Donald G. Moser, Kathleen Higashi, Julie Al-Samarrai, Teeb Kriner, Paula Vaishampayan, Julie Cepeda, Javier Bulterys, Michelle A. Martin, Natasha K. Rios, Phillip Raab, Fredric Emerg Infect Dis Research We assessed video directly observed therapy (VDOT) for monitoring tuberculosis treatment in 5 health districts in California, USA, to compare adherence between 174 patients using VDOT and 159 patients using in-person directly observed therapy (DOT). Multivariable linear regression analyses identified participant-reported sociodemographics, risk behaviors, and treatment experience associated with adherence. Median participant age was 44 (range 18–87) years; 61% of participants were male. Median fraction of expected doses observed (FEDO) among VDOT participants was higher (93.0% [interquartile range (IQR) 83.4%–97.1%]) than among patients receiving DOT (66.4% [IQR 55.1%–89.3%]). Most participants (96%) would recommend VDOT to others; 90% preferred VDOT over DOT. Lower FEDO was independently associated with US or Mexico birth, shorter VDOT duration, finding VDOT difficult, frequently taking medications while away from home, and having video-recording problems (p<0.05). VDOT cost 32% (range 6%–46%) less than DOT. VDOT was feasible, acceptable, and achieved high adherence at lower cost than DOT. Centers for Disease Control and Prevention 2018-10 /pmc/articles/PMC6154139/ /pubmed/30226154 http://dx.doi.org/10.3201/eid2410.180459 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Garfein, Richard S.
Liu, Lin
Cuevas-Mota, Jazmine
Collins, Kelly
Muñoz, Fatima
Catanzaro, Donald G.
Moser, Kathleen
Higashi, Julie
Al-Samarrai, Teeb
Kriner, Paula
Vaishampayan, Julie
Cepeda, Javier
Bulterys, Michelle A.
Martin, Natasha K.
Rios, Phillip
Raab, Fredric
Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA
title Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA
title_full Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA
title_fullStr Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA
title_full_unstemmed Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA
title_short Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA
title_sort tuberculosis treatment monitoring by video directly observed therapy in 5 health districts, california, usa
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154139/
https://www.ncbi.nlm.nih.gov/pubmed/30226154
http://dx.doi.org/10.3201/eid2410.180459
work_keys_str_mv AT garfeinrichards tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT liulin tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT cuevasmotajazmine tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT collinskelly tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT munozfatima tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT catanzarodonaldg tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT moserkathleen tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT higashijulie tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT alsamarraiteeb tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT krinerpaula tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT vaishampayanjulie tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT cepedajavier tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT bulterysmichellea tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT martinnatashak tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT riosphillip tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa
AT raabfredric tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa